News | April 18, 2007

Its Products Seized, Shelhigh Denies FDA Claims of Compromised Safety, Sterility

April 19, 2007 — Following Tuesday’s seizing of all implantable medical devices from Shelhigh Inc., Union, NJ, by FDA investigators and U.S. marshals, the company has responded with denials to FDA claims that its manufacturing processes that may compromise the safety and effectiveness of the products, particularly their sterility. Shelhigh will challenge the decision in Federal Court (07 Civ 1769 WJM, New Jersey).

"I am deeply disappointed by the FDA decision which was made after the full cooperation of Shelhigh during an intensive 10 week inspection of our facility by the FDA," said Shelhigh founder and chief scientific officer, Shlomo Gabbay, M.D. "During this inspection Shelhigh fully addressed all observations raised by FDA personnel, repeatedly requested corrections of statements made by the FDA in their site report, and also repeatedly requested meetings with the FDA to discuss any outstanding issues as well as concerns which arose during the 10 week inspection, and these meetings were also refused by the FDA."

The FDA press release, which was issued the same day the seizure began, also noted that critically ill patients, pediatric patients and immuno-compromised patients may be at greatest risk from the use of these devices.

"These are the very same patients that Shelhigh products have been helping over the past 10 years, extending their lives often when no other solution was available to them, " Dr. Gabbay responded.

Shelhigh No-React products are acknowledged in peer-reviewed scientific journals as offering unique resistance to infection, even in cases of active infective endocarditis (AIE).

Asked about the FDA reference to two warning letters, Dr. Gabbay replied that the first warning letter was from 2000 and all FDA opinions expressed in that letter were addressed, and that the second warning letter issued in 2005 was the one for which Shelhigh has sought verification pertaining to the actions implemented by Shelhigh.

"I can't explain why the FDA sometimes chooses to ignore factual information but it does happen," said Dr. Gabbay. "It is unfortunate that the FDA is stopping Shelhigh from shipping our life-saving products, and I remain hopeful that the FDA will quickly resolve whatever internal issues they have which have lead to their baffling seizure decision," said Dr. Gabbay.

Medical devices manufactured by Shelhigh include:

* Shelhigh Pericardial Patch
* Shelhigh No-React Pericardial Patch
* Shelhigh No-React PneumoPledgets
* Shelhigh No-React VascuPatch
* Shelhigh No-React Tissue Repair Patch/UroPatch
* Shelhigh Pulmonic Valve Conduit No-React Treated
* Shelhigh No-React Dura Shield
* Shelhigh BioRing (annuloplasty ring)
* Shelhigh No-React EnCuff Patch
* Shelhigh No-React Stentless Valve Conduit
* Shelhigh Internal Mammary Artery
* Shelhigh Gold perforated patches
* Shelhigh Pre Curved Aortic Patch (Open)
* Shelhigh NR2000 SemiStented aortic tricuspid valve
* Shelhigh BioConduit stentless valve
* Shelhigh NR900A tricuspid valve
* Shelhigh MitroFast Mitral Valve Repair System
* Shelhigh BioMitral tricuspid valve
* Shelhigh Injectable Pulmonic Valve System

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init